E Fund Hang Seng SCHK Innovative Drug ETF

WuXi Biologics Signs Strategic Collaboration Agreement with Earendil Labs

China BioPharm's TQB3454 Shows Success in Phase III Clinical Trial for Biliary Tract Cancer, Plans to Submit Marketing Application

Sci-Tech Innovation Board Companies Projected Earnings Growth in 2025, Several Companies Expected to 'Delist'

BeiGene Reports First Profit in 2025 with Record Sales

Nichi Xia Cheng B-Type Private Plc Issues 84,033,600 Shares to Wuxi Biologics HealthCare Venture

Stone Pharmaceutical's SYH2059 Inhalation Powder Approved for Clinical Trials by FDA

Jiayao Group's New Drug SYH2059 Receives FDA Approval for Clinical Trials in the U.S.

China Biopharmaceuticals and Sanofi Reach New Drug Licensing Agreement

Stone Pharmaceutical Group's Indacaterol Mometasone Inhalation Powder Approved for Clinical Trials in China

JPMorgan Increases Stake in Innovent Biologics to 5%

CICC Publishes Report on Biogen's FY2022 Revenue Meeting Expectations

Nomura Adjusts Kanghong Biotech Revenue Forecast and Target Price

CanSino and Inovio Partner to Evaluate Efficacy in Glioblastoma Treatment

Stone Pharmaceutical's Emicizumab Injection Receives Approval for Clinical Trials from NMPA

China Biopharmaceutical to Receive Up to $153 Million for Rova-T

Morgan Stanley Predicts China's Biotech Sector to Fluctuate in H1 and See Clearer Direction in H2

Stone Pharmaceutical Group's Injectable Paclitaxel Albumin Nanoparticle Receives FDA Clinical Trial Approval

UBS Names CSPC Pharmaceutical Group as Top Pick in Healthcare Sector

BOA Securities Cuts Revenue Forecast for Zai Lab But Raises Target Price

JPMorgan Adjusts Biogen's Target Price

516500

01877

512290

588860

159849

588250

588130

159316

516820

159506

159859

520690

516930

159837

159992

Junshi Biosciences released its 2025 annual report, with operating revenue reaching 2.498 billion yuan, a year-on-year increase of 28.23%; the net loss attributable to the parent company narrowed to 875 million yuan, a year-on-year reduction of 31.68%. The sales expense ratio decreased to 42.15%, and the sales of the core product Toripalimab reached 2.068 billion yuan, a year-on-year increase of 38%. The company is transitioning from "burning cash for scale" to "refined operations." Although it is still in a negative operating cash flow state, the loss margin continues to narrow, approaching the breakeven point. The operational strategy for 2025 has significantly changed, with refined expense control and improved sales efficiency

腾讯新闻 - 财经

ChinaAMC CSI Biotechnology Theme ETF

JUNSHI BIO

Guotai CSI Bio-medicine ETF

ICBCCS SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Tianhong CNI BIOMEDICINE ETF

Huaan Hang Seng Biotech ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Minsheng Royal CSI Biotechnology Theme ETF

Junshi Biosciences

E Fund CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

Junshi Biosciences 2025 Annual Report: Loss reduction exceeds 30%, dual antibody battlefield welcomes a watershed moment

LABU

IBBQ

513700

520500

562050

159892

512010

Biotechnology startup Earendil Labs plans to go public in Hong Kong, aiming to raise up to $500 million (approximately HKD 3.9 billion). The company has partnerships with well-known pharmaceutical companies such as Sanofi and WuXi Biologics. Meanwhile, integrated circuit design company Guomin Technology and network solutions provider Feisuke Innovation have also begun their initial public offerings, planning to raise HKD 1.03 billion and HKD 1.66 billion, respectively, with strong oversubscription performance on their first day

Stheadline

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

Invesco Nasdaq Biotechnology ETF

Penghua CSI HK Connect Health Care Composite ETF

iShares US Pharma

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

WUXI BIO

Hwabao WP CSI Pharmaceuticals ETF

China Southern Hang Seng Biotech ETF(QDII)

VG Health

China Universal CNI HK Connect Innovative Drugs Industry ETF

Ark Genomic Revolution ETF

iShares Biotechnology ETF

ALPS Medical Breakthrough

WUXI APPTEC

WuXi Biologics

Sanofi

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

E Fund CSI 300 Health Care ETF

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

WuXi AppTec

ChinaAMC SSE Health Care ETF Initiating Fund

VanEck Biotech ETF

SINOMED

First Trust NYSE Arca Biotech Index Fd

Biotech startup Earendil Labs is reported to raise HKD 3.9 billion through a Hong Kong IPO for AI drug development, collaborating with Sanofi and WuXi AppTec

000933

513120

159929

Annovis Bio reported a net loss of $28.9 million for the year, an increase from $24.6 million in 2024, primarily due to higher clinical spending. The company has $19.5 million in cash, which is insufficient to fund operations beyond 12 months, providing a runway into Q3 2026. Key highlights include a pivotal Phase 3 Alzheimer’s trial and a Parkinson’s disease extension study. R&D expenses rose to $25.2 million, while general and administrative costs decreased. Additional fundraising is critical for ongoing trials and operations.

TradingView

800 Health Care

GF CSI All Share Health Care ETF

ChinaAMC CSI All Share Health Care Devices ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Dacheng CSI All Share Health Care Equipment and Services ETF

Bosera Hang Seng Health Care ETF(QDII)

China Universal 800 Health Care ETF

China Universal NASDAQ Biotechnology Technology ETF(QDII)

Annovis Bio 10-K: Net loss $28.9M; Cash $19.5M, runway into Q3 2026

06855

Ascentage Pharma Group International has scheduled a board meeting for March 25, 2026, to approve its annual results for the financial year ending December 31, 2025, and to consider declaring a final dividend. This meeting is crucial for aligning financial reporting and shareholder returns with the company's strategic objectives. The latest analyst rating for Ascentage Pharma (HK:6855) is a Hold, with a price target of HK$46.00. The company focuses on developing innovative therapies for oncology and other diseases, with a current market cap of HK$17.49B.

Tip Ranks

ASCENTAGE-B

Ascentage Pharma Sets March Board Meeting to Approve 2025 Results and Consider Final Dividend

Junshi Biosciences Board Approves 2025 Work Report and Highlights Governance Actions

Junshi Biosciences Board Approves 2025 Work Report and Highlights Governance Actions

589720

Sunshine Lake Pharma Forecasts Turnaround to 2025 Profit

marketscreener

SUNSHINE PHARMA

Guotai SSE STAR Brand Name Drug ETF

Sunshine Lake Pharma Forecasts Turnaround to 2025 Profit

Junshi Biosciences Narrows Loss by 34% in 2025

OBiO Tech

Junshi Biosciences Narrows Loss by 34% in 2025

Fosun Pharma Unit Gets China Nod for Hematological Malignancy Drug Trial

FOSUN PHARMA

Fosun Pharma Unit Gets China Nod for Hematological Malignancy Drug Trial

00867

China Medical System Gets China Nod to Market Renal Anaemia Drug

China Medical System Gets China Nod to Market Renal Anaemia Drug

Pak Fah Yeow Forecasts Rise in 2025 Profit

PAK FAH YEOW

Pak Fah Yeow Forecasts Rise in 2025 Profit

Pak Fah Yeow International expects consolidated net profit attributable of HK$91.3 million for year

Pak Fah Yeow International expects consolidated net profit attributable of HK$91.3 million for year

United Laboratories International expects FY profit RMB2 bln

UNITED LAB

United Laboratories International expects FY profit RMB2 bln

300482

LEGN

02367

Legend Biotech plans to conduct a secondary listing in Hong Kong, expecting to raise between $300 million and $400 million. The company focuses on the development of novel cell therapies and was listed on NASDAQ in 2020, currently having a market capitalization of approximately $3.523 billion

WONDFO BIOTECH

Legend Biotech

GIANT BIOGENE

iShares Global Healthcare

Direxion S&P Biotech Bear 3X

Health Care Select Sector SPDR

Legend Biotech plans to go public in Hong Kong, with an IPO fundraising of up to 400 million USD

WuXi Biologics Signs Antibody Development Deal with Earendil Labs

Eledon Pharmaceuticals

WuXi Biologics Signs Antibody Development Deal with Earendil Labs

Junshi Biosciences Returns 1.1 Billion Yuan Idle Proceeds to Designated Account

Junshi Biosciences Returns 1.1 Billion Yuan Idle Proceeds to Designated Account

E Fund Hang Seng SCHK Innovative Drug ETF(159316.SZ)

Junshi Biosciences 2025 Annual Report: Loss reduction exceeds 30%, dual antibody battlefield welcomes a watershed moment

Biotech startup Earendil Labs is reported to raise HKD 3.9 billion through a Hong Kong IPO for AI drug development, collaborating with Sanofi and WuXi AppTec

Annovis Bio 10-K: Net loss $28.9M; Cash $19.5M, runway into Q3 2026

Ascentage Pharma Sets March Board Meeting to Approve 2025 Results and Consider Final Dividend

Junshi Biosciences Board Approves 2025 Work Report and Highlights Governance Actions